Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGENASDAQ:GTHXNASDAQ:MESONASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$39.25+3.9%$35.40$26.20▼$63.50$1.77B1.72514,323 shs486,858 shsGTHXG1 Therapeutics$7.15$7.13$1.08▼$7.19$373.81M1.661.70 million shsN/AMESOMesoblast$11.40-4.3%$12.60$5.78▼$22.00$1.45B3.48271,471 shs92,809 shsVERAVera Therapeutics$23.37-2.6%$24.93$18.53▼$51.61$1.49B1.28746,268 shs767,031 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics-0.03%+6.42%-4.88%-6.30%-22.90%GTHXG1 Therapeutics0.00%0.00%0.00%0.00%+92.20%MESOMesoblast+4.38%+9.67%-1.65%-39.08%+67.75%VERAVera Therapeutics+2.52%+12.20%-9.88%-36.73%-42.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPGEApogee Therapeutics2.2159 of 5 stars3.50.00.00.03.14.20.0GTHXG1 Therapeutics0.4352 of 5 stars1.00.00.03.80.00.00.6MESOMesoblast1.7726 of 5 stars3.52.00.00.01.50.80.6VERAVera Therapeutics2.9469 of 5 stars3.63.00.00.04.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 3.00Buy$92.17134.82% UpsideGTHXG1 Therapeutics 2.00Hold$4.00-44.06% DownsideMESOMesoblast 3.00Buy$18.0057.89% UpsideVERAVera Therapeutics 3.20Buy$64.67176.71% UpsideCurrent Analyst Ratings BreakdownLatest GTHX, VERA, APGE, and MESO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025MESOMesoblastCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/13/2025APGEApogee TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$95.003/11/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.003/4/2025MESOMesoblastCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/4/2025VERAVera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$77.00 ➝ $71.003/3/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.002/27/2025VERAVera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$59.00 ➝ $61.002/10/2025APGEApogee TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy2/7/2025MESOMesoblastPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$15.00 ➝ $24.002/4/2025VERAVera TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$49.002/3/2025VERAVera TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$7.50 per shareN/AGTHXG1 Therapeutics$58.20M6.42N/AN/A$0.68 per share10.51MESOMesoblast$5.67M255.45N/AN/A$4.21 per share2.71VERAVera TherapeuticsN/AN/AN/AN/A$1.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$83.99M-$3.29N/AN/AN/AN/A-21.81%-20.94%5/12/2025 (Estimated)GTHXG1 Therapeutics-$47.97M-$0.62N/AN/AN/A-76.93%-136.98%-39.33%N/AMESOMesoblast-$87.96MN/A0.00N/AN/AN/AN/AN/AN/AVERAVera Therapeutics-$95.99M-$2.75N/AN/AN/AN/A-50.13%-39.50%5/8/2025 (Estimated)Latest GTHX, VERA, APGE, and MESO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025APGEApogee Therapeutics-$1.19N/AN/AN/AN/AN/A5/8/2025Q1 2025VERAVera Therapeutics-$0.75N/AN/AN/AN/AN/A3/3/2025Q4 2024APGEApogee Therapeutics-$0.94-$1.19-$0.25-$1.19N/AN/A2/26/2025Q4 2024VERAVera Therapeutics-$0.83-$0.72+$0.11-$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/AGTHXG1 TherapeuticsN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A16.3916.39GTHXG1 Therapeutics1.342.482.12MESOMesoblast0.211.181.18VERAVera Therapeutics0.1713.7613.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%GTHXG1 Therapeutics24.21%MESOMesoblast1.43%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics36.10%GTHXG1 Therapeutics6.11%MESOMesoblast18.80%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9145.03 million28.77 millionOptionableGTHXG1 Therapeutics17052.28 million49.09 millionOptionableMESOMesoblast80127.05 million103.17 millionOptionableVERAVera Therapeutics4063.75 million49.58 millionOptionableGTHX, VERA, APGE, and MESO HeadlinesRecent News About These CompaniesVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by First Light Asset Management LLCApril 30 at 8:13 AM | marketbeat.comRaymond James Financial Inc. Purchases Shares of 69,724 Vera Therapeutics, Inc. (NASDAQ:VERA)April 30 at 3:48 AM | marketbeat.comVoya Investment Management LLC Buys 591,682 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)April 29 at 5:48 AM | marketbeat.comAdage Capital Partners GP L.L.C. Reduces Position in Vera Therapeutics, Inc. (NASDAQ:VERA)April 29 at 5:38 AM | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Price T Rowe Associates Inc. MDApril 29 at 5:07 AM | marketbeat.comBarclays PLC Raises Position in Vera Therapeutics, Inc. (NASDAQ:VERA)April 29 at 3:51 AM | marketbeat.comRenaissance Technologies LLC Makes New Investment in Vera Therapeutics, Inc. (NASDAQ:VERA)April 29 at 3:49 AM | marketbeat.comNovartis' VANRAFIA Approval Disrupts IgA Nephropathy Market, Paving Way for New Therapeutic Paradigm | DelveInsightApril 28 at 7:20 PM | prnewswire.co.ukDecheng Capital LLC Reduces Position in Vera Therapeutics, Inc. (NASDAQ:VERA)April 28 at 7:20 AM | marketbeat.comLord Abbett & CO. LLC Increases Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)April 28 at 5:56 AM | marketbeat.comT. Rowe Price Investment Management Inc. Buys 431,178 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)April 28 at 5:26 AM | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by Wells Fargo & Company MNApril 28 at 3:24 AM | marketbeat.comVera Therapeutics Target of Unusually Large Options Trading (NASDAQ:VERA)April 25, 2025 | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Eversept Partners LPApril 24, 2025 | marketbeat.comWhy Vera Therapeutics, Inc.’s (VERA) Stock Is Up 6.17%April 24, 2025 | aaii.comAvoro Capital Advisors LLC Has $237.25 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA)April 23, 2025 | marketbeat.comRock Springs Capital Management LP Boosts Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)April 23, 2025 | marketbeat.comMarshall Wace LLP Increases Position in Vera Therapeutics, Inc. (NASDAQ:VERA)April 21, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Altium Capital Management LLCApril 19, 2025 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Down 2.6% - Should You Sell?April 16, 2025 | marketbeat.comGeode Capital Management LLC Has $48.79 Million Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)April 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatThe 3 Most Talked About Investments on WallStreetBets Right NowBy Leo Miller | April 2, 2025View The 3 Most Talked About Investments on WallStreetBets Right NowCan IBM’s Q1 Earnings Spark a Breakout for the Stock?By Jeffrey Neal Johnson | April 23, 2025View Can IBM’s Q1 Earnings Spark a Breakout for the Stock?Is McDonald’s Stock Serving a Value Meal to Investors? By Jeffrey Neal Johnson | April 13, 2025View Is McDonald’s Stock Serving a Value Meal to Investors? Why It May Be Time to Buy CrowdStrike Stock Heading Into EarningsBy Chris Markoch | April 24, 2025View Why It May Be Time to Buy CrowdStrike Stock Heading Into EarningsGTHX, VERA, APGE, and MESO Company DescriptionsApogee Therapeutics NASDAQ:APGE$39.25 +1.47 (+3.89%) As of 04:00 PM EasternApogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.G1 Therapeutics NASDAQ:GTHXG1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Mesoblast NASDAQ:MESO$11.40 -0.51 (-4.28%) As of 04:00 PM EasternMesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Vera Therapeutics NASDAQ:VERA$23.37 -0.63 (-2.63%) As of 04:00 PM EasternVera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
